Search Results
Aug 20, 2026, 19:10 ET Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
rates. In July, the Company announced topline end-of-treatment data from its Phase 2b ENRICH and ENHANCE studies.At EOT, the ENRICH study evaluating pre-treatment with BRII-179 followed by elebsiran and PEG-IFNα achieved HBsAg loss rates of 42.9% (42/98) and 40.0% (20/50)
More news about: Brii Biosciences Limited
Jul 02, 2026, 20:00 ET Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
Officer of the Company. "While longer-term follow-up is needed to assess durability of the HBsAg loss, the data observed to date, together with EOT and post-EOT findings from multiple prior studies, are very consistent, suggesting that the ENRICH study design is preferred for a registrational study. We
More news about: Brii Biosciences Limited
Jun 15, 2026, 11:00 ET Allora Labs 與 Vodafone 旗下的 Pairpoint 將為物聯網經濟建立一套預測智能層
這類合作正反映出人工智能的構建和部署方式正在轉變：不再是某個單一供應商擁有的黑箱，而是在整個生態系統中彼此共享、不斷競爭並持續進步的智能層。對於機器學習建構者而言，這是邀請他們從實驗階段邁向真正產生影響的階段。關於 Vodafone 旗下的 PairpointPairpoint 是由 Vodafone Group 與 Sumitomo Corporation 共同創立的物聯網經濟 (EoT) 合資公司。 成立宗旨是在全球規模上實現自主的機器對機器識別、連接及交易執行。借助 Vodafone 廣闊的物聯網足跡及穩固的數碼身份技術，Pairpoint 的平台令裝置、車輛、感應器及機器得以在無人介入的情況下，彼此協調、交易並自行決策。Pairpoint 擁有區塊鏈技術支援的後端系統，並原生支援去中心化結算，因此能在出行、物流、能源及互聯基建等領域，開創全新類別的按使用量付費服務。關於
More news about: Allora Labs
Jun 15, 2026, 11:00 ET Allora LabsとPairpoint by Vodafone、「モノの経済」向けの予測インテリジェンス層を構築へ
促すものです。Pairpoint by VodafoneについてPairpointは、Vodafone GroupとSumitomo Corporationによる「モノの経済（Economy of Things、EoT）」の合弁会社です。世界規模で機械間の自律的な識別、接続、取引実行を可能にするために設立されました。Vodafoneが広範に展開するIoT基盤と安全なデジタルID機能を活用するPairpointのプラットフォームにより、デバイス、車両、センサー、機械は、人の介入なしに連携し、取引を行い、意思決定を下すことができます。
More news about: Allora Labs
Jun 15, 2026, 11:00 ET Allora Labs and Pairpoint by Vodafone to Build a Predictive Intelligence Layer for the Economy of Things
builders, it's an invitation to move from experiments to impact.About Pairpoint by VodafonePairpoint is the Economy of Things (EoT) joint venture by Vodafone Group and Sumitomo Corporation. Established to enable autonomous machine-to-machine identification, connectivity, and transaction
More news about: Allora Labs
Jun 15, 2026, 11:00 ET Allora Labs and Pairpoint by Vodafone to Build a Predictive Intelligence Layer for the Economy of Things
builders, it's an invitation to move from experiments to impact.About Pairpoint by VodafonePairpoint is the Economy of Things (EoT) joint venture by Vodafone Group and Sumitomo Corporation. Established to enable autonomous machine-to-machine identification, connectivity, and transaction
More news about: Allora Labs
Jun 15, 2026, 11:00 ET Allora Labs und Pairpoint by Vodafone entwickeln für die Economy of Things eine Ebene für prädiktive Intelligenz
überzugehen.Informationen zu Pairpoint by VodafonePairpoint ist das Joint Venture von Vodafone Group und Sumitomo Corporation für die Economy of Things (EoT). Gegründet, um autonome Maschine-zu-Maschine-Identifizierung, Konnektivität und Transaktionsabwicklung auf globaler Ebene zu ermöglichen.Durch
More news about: Allora Labs
Jun 15, 2026, 11:00 ET Allora Labs y Pairpoint by Vodafone crearán una capa de inteligencia predictiva para la economía de las cosas
pasar de la experimentación al impacto.Acerca de Pairpoint by Vodafone Pairpoint es la empresa conjunta de Economía de las Cosas (EoT) de Vodafone Group y Sumitomo Corporation. Fue creada para permitir la identificación, conectividad y ejecución de transacciones autónomas entre máquinas
More news about: Allora Labs
Jun 15, 2026, 11:00 ET Allora Labs et Pairpoint by Vodafone développeront une couche d'intelligence prédictive dédiée à l'économie des objets
d'expérimentation à celle de l'impact.À propos de Pairpoint by VodafonePairpoint est la coentreprise de l'économie des objets (EoT) créée par le groupe Vodafone et Sumitomo Corporation. La société a été créée pour permettre l'identification, la connectivité et l'exécution de transactions
More news about: Allora Labs
Jun 09, 2026, 09:30 ET P. Terry's Burger Stand Transitions to Employee Ownership Trust, Benefitting 1,800 Employees
By transitioning to an Employee Ownership Trust (EOT), the company is establishing a structure that allows employees to share in the long-term value of the business. The EOT will hold shares on behalf of employees while helping preserve the company's independence,
More news about: Common Trust
May 27, 2026, 07:00 ET Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
another evaluating a sequential regimen of BRII-179 and elebsiran for 24 weeks followed by triple combination therapy for 24 weeks. End-of-treatment (EOT) data from both studies are expected to be presented in 2026."We are encouraged by the consistency of the findings observed throughout the ENSURE
More news about: Brii Biosciences Limited
Apr 26, 2026, 07:00 ET Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
the Study of the Liver (APASL 2026), taking place from April 22-25, 2026 in Istanbul, Turkey. This analysis evaluated post-end-of-treatment (EOT) HBsAg rebound in NRTI-experienced participants with chronic hepatitis B virus (HBV) infection who achieved HBsAg loss in the Phase 2 ENSURE study or
More news about: Brii Biosciences Limited
Mar 26, 2026, 08:42 ET After 37 Years of Purpose, Natracare's Founder Passes the Torch to the People Who Helped Build It
category, today announced that it has transitioned to an employee-owned company through the establishment of the Natracare Employee Ownership Trust (EOT). After 37 years of building something she truly believed in, founder Susie Hewson has chosen to place the company's future into the hands of the people
More news about: Natracare
Mar 19, 2026, 07:00 ET Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
advancement of its late-stage hepatitis B virus (HBV) portfolio toward higher functional cure rates. The Company presented 24-week post end of treatment (EOT) follow-up data from Cohort 4 of its ongoing Phase 2b ENSURE study at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®,
More news about: Brii Biosciences Limited
Mar 09, 2026, 08:01 ET Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
ibezapolstat. Notably, in the combined Phase 2 trial, 100% (25 of 25) ibezapolstat-treated patients) who had Clinical Cure at EOT) (End of Treatment) remained cured through one month after EOT, as compared to 86% (12 of 14) for the vancomycin patient group.Ibezapolstat was well-tolerated, with no serious
More news about: Acurx Pharmaceuticals, Inc.
Feb 02, 2026, 08:42 ET Keep it Local: Softstar Shoes
thirty employees in Oregon's central valley. Softstar recently transitioned to employee ownership using a model called an Employee-Owned Trust (EOT). While this is a common model in the United Kingdom, it's relatively new in the USA and is gaining traction, and for good reason. A Trust is unique
More news about: Softstar Shoes
Dec 10, 2025, 09:00 ET First in Indiana, Among the First in the U.S.: Guidon Pioneers Employee Ownership Trust
Guidonnaires.Local Legacy, Long-Term Stability: The EOT model ensures Guidon remains independently owned and operated, preserving its purpose.Guidon partnered with Common Trust, a national leader in employee ownership transitions, to establish the EOT. This partnership ensured that Guidon's mission
More news about: Common Trust
Nov 18, 2025, 08:00 ET Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
ibezapolstat. Notably, in the combined Phase 2 trial, 100% (25 of 25) ibezapolstat-treated patients) who had Clinical Cure at EOT) (End of Treatment) remained cured through one month after EOT, as compared to 86% (12 of 14) for the vancomycin patient group. Ibezapolstat was well-tolerated, with no serious adverse
More news about: Acurx Pharmaceuticals, Inc.
Nov 10, 2025, 08:30 ET Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B
loss benefit in the BRII-179 responder group was sustained over time. At EOT, 58% (11/19) HBsAg loss was observed in BRII-179 anti-HBs responders. In anti-HBs non-responders, only 17% (2/12) achieved HBsAg loss. At 24 weeks post EOT, 42% (8/19) of anti-HBs responders maintained HBsAg loss compared to 8%
More news about: Brii Biosciences Limited
Nov 10, 2025, 08:30 ET 騰盛博藥在2025年AASLD大會上發佈ENSURE II期研究最新突破性數據，進一步強調BRII-179作為慢乙肝治癒性療法的潛力
BRII-179 抗 -HBs 應答者，在治療結束（ EOT ）後 24 周仍維持 HBsAg 清除狀態。
More news about: 騰盛博藥生物科技有限公司
Nov 10, 2025, 08:00 ET Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
ibezapolstat. Notably, in the combined Phase 2 trial, 100% (25 of 25) ibezapolstat-treated patients) who had Clinical Cure at EOT) (End of Treatment) remained cured through one month after EOT, as compared to 86% (12 of 14) for the vancomycin patient group. Ibezapolstat was well-tolerated, with no serious adverse
More news about: Acurx Pharmaceuticals, Inc.
Nov 07, 2025, 08:30 ET Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine
results from this publication include: Cohorts 1-3: At 24 weeks post-EOT, HBsAg loss was observed in 4 of 19 participants (21.1%) in Cohort 2 (elebsiran 200 mg + PEG-IFNα) and 6 of 18 participants (33.3%) in Cohort 3 (elebsiran
More news about: Brii Biosciences Limited
Nov 05, 2025, 09:00 ET Common Trust Facilitates Cypress Valley Meat Company Employee Ownership Trust, Deepening Their Commitment to Employees
Employee Ownership Trust in the state of Arkansas, and even more specifically, makes them the first EOT within the meat processing community. "With the establishment of an EOT, our employees can get a more immediate payout through annual profit-sharing programs," said Cypress Valley
More news about: Common Trust
Oct 28, 2025, 08:00 ET Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference
ibezapolstat. Notably, in the combined Phase 2 trial, 100% (25 of 25) ibezapolstat-treated patients) who had Clinical Cure at EOT) (End of Treatment) remained cured through one month after EOT, as compared to 86% (12 of 14) for the vancomycin patient group. Ibezapolstat was well-tolerated, with no serious adverse
More news about: Acurx Pharmaceuticals, Inc.
Sep 30, 2025, 07:30 ET Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection
ibezapolstat. Notably, in the combined Phase 2 trial, 100% (25 of 25) ibezapolstat-treated patients) who had Clinical Cure at EOT) (End of Treatment) remained cured through one month after EOT, as compared to 86% (12 of 14) for the vancomycin patient group. Ibezapolstat was well-tolerated, with no serious adverse
More news about: Acurx Pharmaceuticals, Inc.